Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS research · 2026-04-16

Clinical Trial Update: A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine [Phase 3]

View source ↗

Summary

Pfizer is conducting a Phase 3 trial to study rimegepant for intermittent prevention of menstrual migraine in women, and the study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • NURTEC ODT (RIMEGEPANT SULFATE)

Snippet

Sponsor: Pfizer | Conditions: Menstrual Migraine | Phase 3 | Status: RECRUITING